18,266 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Acquired by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 18,266 shares of the company’s stock, valued at approximately $79,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Cardiff Oncology by 11.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock valued at $324,000 after purchasing an additional 12,503 shares in the last quarter. State Street Corp increased its position in Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after buying an additional 27,628 shares during the last quarter. XTX Topco Ltd raised its holdings in Cardiff Oncology by 44.3% during the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock valued at $321,000 after buying an additional 36,947 shares in the last quarter. Barclays PLC lifted its position in shares of Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after buying an additional 39,542 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Cardiff Oncology by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock worth $2,479,000 after acquiring an additional 17,557 shares in the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on CRDF shares. HC Wainwright raised their price objective on Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Piper Sandler lifted their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, December 13th.

Cardiff Oncology Stock Down 4.4 %

Shares of NASDAQ CRDF opened at $3.29 on Friday. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $6.38. The company has a market cap of $218.86 million, a P/E ratio of -3.50 and a beta of 1.73. The business’s 50 day moving average is $3.99 and its two-hundred day moving average is $3.44.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.